Amryt Pharma files registration statement for impending Nasdaq listing

Amryt Pharma, which makes treatments for rare conditions, has filed a registration statement for its impending US listing on the Nasdaq.

The company, which recently signed an agreement with Swixx BioPharma of Switzerland for the distribution of its drug Myalepta (metreleptin), said it is not proposing to register any new issuance of securities.

“The registration statement is subject to ongoing review by the US Securities and Exchange Commission (SEC), and the proposed listing of American Depositary Shares (ADSs) representing the company’s shares is subject to approval by Nasdaq,” it said.

Amryt reported combined revenues of $154.1 million (€142 million) in 2019, 13.1 per cent higher than the previous year.

Finding a Covid-19 test: ‘It was like learning to fly a jumbo jet in mid-air’

---

Galway pharma firm shipping animal products to lucrative US market

---

Taking on the US pet health market from Galway at age 72

---

Pharma research firm APC partners to develop Covid-19 vaccine

---

Amryt has been pursuing trials of a potential treatment for a rare hereditary condition, “butterfly skin”, or epidermolysis bullosa, which leads to the blistering of the skin in patients at the slightest touch.